Root Cause ≠ Treatment Priority
The most causally fundamental mechanism in ME/CFS is not necessarily the best treatment target. This seems wrong at first. Surely the most upstream cause deserves the most aggressive intervention? The logic breaks down in three separate ways, and understanding why has real consequences for how you think about treatment strategy.
1 Three reasons root cause and treatment priority diverge
The first is that the root cause may no longer be present. Most ME/CFS patients are diagnosed years after onset. The triggering event — a viral infection, a period of extreme physiological stress, surgery — resolved long ago; the virus was cleared, the stressor ended, and the wound healed. Yet the disease persists, because the amplifier mechanisms the trigger set in motion have become self-sustaining. The original cause is gone; the locks it established remain. In this situation, treating the original trigger achieves nothing, since it is no longer active. The clinically relevant question is not “what caused your ME/CFS?” but “what is maintaining it now?” Those can be very different answers [Ch. 16 §Treatment Implications of the Causal Hierarchy].
The second reason is that the most upstream cause may be the least accessible. CNS energy metabolism cannot be directly restored with available therapeutics. You cannot inject ATP into the brain, pharmacologically repair neurovascular coupling with targeted precision, or reverse microglial activation without broad immunosuppression. The most causally fundamental mechanism, if it is the CNS energy crisis, is also the least therapeutically reachable with current tools [Ch. 16 §Treatment Implications of the Causal Hierarchy]. Meanwhile, downstream amplifiers like mast cell activation (addressable with antihistamines and mast cell stabilizers, with established safety profiles and rapid onset [Ch. 16 §Mast Cell–Energy Loop]) or NAD⁺ depletion (addressable with NR/NMN supplementation [Ch. 16 §NAD⁺ Depletion Spiral]) are accessible now. Their causal rank may be lower, but their therapeutic rank can be higher precisely because they can be reached.
The third reason is that single-mechanism treatments fail by design in a multi-lock disease. Even if a root cause is both currently active and therapeutically accessible, treating it alone may fail. ME/CFS is maintained by several self-reinforcing processes simultaneously; address one and the others sustain the disease state independently. Recovery requires releasing enough locks at once that the remaining ones can no longer hold the system [Ch. 16 §Treatment Implications of the Causal Hierarchy]. The relevant question is never “which single mechanism should we target?” but “which combination of mechanisms, addressed simultaneously, enables escape from the disease attractor?”
2 Treatment priority as a product of two axes
Treatment priority should be determined by the product of causal importance and therapeutic tractability, not causal importance alone [Ch. 16 §Treatment Implications of the Causal Hierarchy]. A mechanism that is highly causal but currently inaccessible has low treatment priority — you cannot treat what you cannot reach. A mechanism that is moderately causal but highly tractable may rank higher because it contributes to the combination needed for disease escape and can be acted on now.
Applying this reasoning to the full mechanism classification from Ch. 16 [§Treatment Priority Table] produces a ranking that diverges substantially from the causal hierarchy. The GPCR autoantibody cascade ranks first: it is a root cause with moderate-to-high tractability, since immunoadsorption and daratumumab demonstrate real-world feasibility and the 60% response rate in the daratumumab pilot is among the highest reported for any ME/CFS intervention [Ch. 16 §GPCR Autoantibody Cascade]. The mast cell activation loop ranks second, not because it is causally primary but because antihistamines and mast cell stabilizers are safe, widely available, and produce rapid symptomatic relief, and because stabilizing this loop improves quality of life immediately while slower, more structurally fundamental treatments take effect. NAD⁺ depletion ranks third: NR/NMN supplementation addresses a key amplifier of energy failure, and benefits accrue over weeks without significant safety concerns.
Epigenetic consolidation ranks fourth, which is notable because it is a load-bearing amplifier that is hard to address with current tools [Ch. 16 §Epigenetic Consolidation, §Load-Bearing versus Secondary Locks]. The more practical implication is prevention: early intervention, before consolidation deepens, is far more feasible than reversal of established consolidation, and this argues for aggressive early treatment rather than a wait-and-see approach.
The CNS energy crisis, ranked as the most causally important mechanism in the entire framework, appears at rank seven. No current intervention can directly and selectively address it; transcranial photobiomodulation, intranasal insulin, and hyperbaric oxygen are all experimental with limited ME/CFS-specific data.
3 Why the most important mechanism ranks seventh
Causal importance and therapeutic tractability are orthogonal axes. A mechanism can occupy the most important position on one and a poor position on the other, and treatment strategy must navigate both. The CNS energy crisis ranking seventh is not an error in the reasoning; it is the point.
This does not mean CNS-targeted approaches should be abandoned. It means they belong further down the immediate treatment sequence. In practice, the sequence should run roughly as follows: begin with tractable interventions that provide immediate symptomatic relief, add root-cause-targeting interventions where the mechanism is likely still active and accessible, and incorporate experimental approaches targeting low-tractability mechanisms as the evidence base develops.
4 What this predicts about clinical trials
The same reasoning explains a pattern that has frustrated ME/CFS treatment research for decades: the near-universal disappointment of single-target trials. If the disease is multi-lock, and if the correct treatment priority is “accessible and combinable” rather than “most causally upstream,” then a trial testing a single highly causal agent against placebo is almost structurally guaranteed to produce a modest or null result. Not because the agent does not work, but because the trial design is testing a single intervention against a disease that cannot be moved by single interventions [Ch. 16 §Research Implications].
The framework predicts this. It also suggests what a more productive trial design would look like: stratify by active mechanism, combine interventions targeting different parts of the lock architecture, and measure not just symptom improvement but changes in disease trajectory [Ch. 16 §Research Implications].
Previous article in this series: Load-Bearing Walls vs. Interior Walls (2026-04-13)
Next: Why Single-Target Treatments Keep Failing in ME/CFS — the multi-lock trap model and what it predicts about treatment design